FDA approves single-dose monthly injector for cholesterol drug

The Food and Drug Administration recently approved Amgen's Repatha Pushtronex system.

Repatha is a drug intended to treat patients with high cholesterol. The Pushotronex system offers a new, monthly single-dose administration option for the drug.

The device, created in conjunction with West Pharmaceutical Services in Exton, Pa., attaches to the body, allowing for hands-free administration.

The medicine may also be administered twice a week through the SureClick autoinjector.

Amgen, based in Thousand Oaks, Calif., expects the Pushtronex system to hit the market in early August.

More articles on supply chain:

Anti-HIV drug largely underused in San Francisco: 5 things to know
Drug monitoring programs show reduction in opioid overdoses: 6 things to know
FDA stops Juno's cancer drug trials after 3 patients die

Copyright © 2025 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


You can unsubscribe from these communications at any time. For more information, please review our Privacy Policy
.
 

Articles We Think You'll Like